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Abstract
Introduction To assess the value of the Mini-Mental State Examination (MMSE)-score at baseline in predicting survival in 
adult primary central nervous system lymphoma (PCNSL) patients.
Methods In the HOVON 105/ ALLG NHL 24 phase III study patients with newly-diagnosed PCNSL were randomized 
between high-dose methotrexate-based chemotherapy with or without rituximab. Data on potential (MMSE-score), and 
known baseline prognostic factors (age, performance status, serum LDH, cerebrospinal fluid total protein, involvement of 
deep brain structures, multiple cerebral lesions, and the IELSG-score) were collected prospectively. Multivariable stepwise 
Cox regression analyses were used to assess the prognostic value of all factors on progression-free survival (PFS) and overall 
survival (OS) among patients with available MMSE score at baseline. Age was analyzed as continuous variable, the MMSE-
score both as a continuous and as a categorical variable.
Results In univariable analysis, age, MMSE-score and whether the patient received rituximab were statistically significantly 
prognostic factors for PFS. Age and MMSE-score were statistically significantly associated with OS. In a multivariable 
analysis of the univariately significant factors only MMSE-score was independently associated with the survival endpoints, 
as a continuous variable (HR for PFS 1.04, 95% CI 1.01–1.08; OS 1.06 (95% CI 1.02–1.10) and as categorical variable HR 
(< 27 versus ≥ 27 for PFS 1.55 (1.02–2.35); OS 1.68 (1.05–2.70). In our population, performance status, serum LDH, and 
CSF protein level were not of prognostic value.
Conclusion Neurocognitive disturbances, measured with the MMSE at baseline, are an unfavorable prognostic factor for 
both PFS and OS in adult PCNSL patients up to 70 years-old.
Keywords MMSE · Primary central nervous system lymphoma · Prognosis
Introduction
Primary central nervous system lymphoma (PCNSL) is a 
rare non-Hodgkin lymphoma confined to the brain, leptome-
ninges, spinal cord and eyes. Over the last decades prognosis 
has improved significantly [1]. Although several prognos-
tic factors have been identified and prognostic models have 
been developed, it remains difficult to predict the prognosis 
of individual patients.
Two prognostic models are currently widely used in 
PCNSL patients: the externally validated Memorial Sloan 
Kettering Cancer Center (MSKCC) prognostic score: [2]
age (> 50 years-old) and Karnofsky Performance score 
(KPS; < 70), and the International Extranodal Lymphoma 
Study Group (IELSG) score: age (> 60 years-old), WHO/
ECOG Performance Status (PS; > 1), Lactate dehydrogenase 
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(LDH) serum level, cerebrospinal fluid (CSF) protein level 
and involvement of deep brain structures [3].
The Mini-Mental State Examination (MMSE) [4] is a 
crude screening tool for neurocognitive impairment. In low- 
and high-grade glioma, the MMSE-score was an independ-
ent prognostic factor for both progression free survival (PFS) 
and overall survival (OS) [5, 6].
In PCNSL patients, data regarding the prognostic value of 
the MMSE are scarce, despite the fact that cognitive symp-
toms occur frequently (up to 43%) in this disease [7]. One 
study describes 95 elderly (> 60 years-old) PCNSL patients, 
and found that MMSE-score ≤ 24 was the only independent 
prognostic factor for OS, while age and PS were not [8]. In 
the present study we aimed to assess whether the MMSE-
score at baseline was independently prognostic for both 
PFS and OS, in a large trial population with adult PCNSL 
patients up to 70 years-old.
Methods
Patients
Patients in the HOVON 105/ALLG NHL 24 study, a large 
multicenter phase III randomized controlled trial (RCT) 
in immunocompetent adults with newly diagnosed CD20 
positive B-cell PCNSL with WHO/ECOG PS 0–3, were 
included [9]. The treatment regimen consisted of two cycles 
of high-dose methotrexate-based chemotherapy, with or 
without rituximab, followed by high-dose-cytarabine. 
Patients < 61 years-old subsequently received 30 Gy whole 
brain radiotherapy. The study was approved by the ethics 
committee at all participating centers and all participants 
gave informed consent. Patients underwent an MMSE at 
baseline, before chemo(-immuno)therapy was initiated, if 
possible.
Baseline characteristics
All patients for whom an MMSE-score at baseline was 
available were included in this study. In addition, the fol-
lowing information was collected: sex, age, WHO/ECOG 
PS, treatment arm, CSF protein and serum LDH levels 
at baseline and whether the patient had multiple cerebral 
lesions, involvement of deep brain structures (periventricular 
regions, basal ganglia, brainstem and/ or cerebellum), and 
whether they received rituximab.
Statistical analysis
First, baseline characteristics, treatment details and survival 
between those who participated in this side-study and those 
who could not due to missing MMSE-scores at baseline 
were compared to assess possible imbalances. Differences 
were tested using a Chi-Square test for categorical data, and 
a Kruskal–Wallis test for continuous data. In addition, the 
median MMSE score per IELSG-score (i.e. 0–1, 2–3, and 
4–5) was calculated.
Subsequently, all the above mentioned individual prog-
nostic factors, as well as the composite IELSG-score, were 
assessed for association with PFS and OS using univariable 
Cox regression analysis. PFS was defined as time from ran-
domization to progression, relapse or death from any cause, 
whichever came first. OS was defined as time from randomi-
zation to death from any cause, which are the same defini-
tions as used in the HOVON 105/ ALLG NHL 24 trial [9]. 
Patients still alive at the date of last contact were censored. 
MMSE was included both as a continuous variable and as 
categorical variable (< 27 or ≥ 27). The cut-off of 27 was 
chosen, based on previous recommendations [10, 11]. Age 
was included as a continuous variable. ECOG PS (≤ 1 ver-
sus > 1), serum LDH (above versus below local upper limit 
of normal), and CSF protein (above versus below cut-off val-
ues according to the IELSG score[3]) were included as cat-
egorical variables. Factors that were statistically significant 
in univariable analysis were included in the stepwise multi-
variable Cox proportional hazards models. A p-value < 0.05 
was considered statistically significant. All analyses were 
performed with Stata version 15.
Results
MMSE-score at baseline was available for 153 of the 199 
(77%) trial patients. There were no significant differences 
between those who were included and those who were not 
regarding baseline characteristics and survival, Supplemen-
tal Table 1 and Supplemental Fig. 1a and b.
Stratified by the IELSG-score, there was difference in 
median (range) MMSE-score at baseline: 29 (11–30) in the 
IELSG 0–1 group and 25 (6–30) in the 2–3 group. In the 
IELSG 4–5 group the median score was 26 (7–29), but only 
5 patients were in this group, Supplemental Table 2).
In the univariable regression analyses age, receipt of 
rituximab and baseline MMSE-score were associated with 
PFS. Only age and MMSE were statistically significant 
predictors of OS (Table 1). In multivariable analysis, only 
MMSE-score at baseline was independently associated 
with both PFS and OS. We found that each unit decrease 
in MMSE-score was associated with a poorer prognosis: 
for PFS (Hazard Ratio [HR], 95% confidence interval [CI] 
1.04, 1.01–1.08) and OS (HR 95% CI 1.06, 1.02–1.10), 
Table 2. When including the MMSE-score as categori-
cal variable in multivariable analyses, corrected for age 
and rituximab, a baseline-score < 27 (as compared to a 
score ≥ 27) was the only factor associated with PFS (HR 
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1.55, 95% CI 1.02–2.35) and overall survival (HR 1.68, 
95% CI 1.05–2.70), Table 2 and Fig. 1. After adding the 
IELSG-score to the other prognostic factors in the multi-
variable analysis, the MMSE-score at baseline remained 
Table 1  Univariate and 
multivariate Cox regression 
analysis for all risk factors with 
MMSE as a continuous variable 
for the progression-free survival 
and overall survival
Hazard ratio’s (HR) and 95% confidence intervals (CI) are shown with their p-value. WHO World Health 
Organization, ECOG Eastern Cooperative Oncology Group, CSF cerebrospinal fluid, LDH lactate dehydro-
genase, ULN upper limit of normal, MMSE mini-mental state examination, IELSG International Extranodal 
Lymphoma Study Lymphoma Study Group
n Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Progression-free survival
 Female 153 0.85 (0.57–1.28) 0.44
 Age (increase; unit = 10 years) 153 1.33 (1.04–1.71) 0.025 1.28 (0.99–1.65) 0.061
 WHO/ECOG > 1 153 0.92 (0.57–1.50) 0.74
 Multiple lesions 138 0.89 (0.58–1.37) 0.59
 Deep structures involved 153 1.39 (0.92–2.09) 0.39
 Elevated CSF total protein 93 0.78 (0.45–1.37) 0.40
 LDH > ULN 153 1.19 (0.77–1.82) 0.44
 Rituximab 153 0.66 (0.44–1.00) 0.049 0.69 (0.45–1.04) 0.075
 MMSE (decrease unit = 1 point) 153 1.05 (1.01–1.08) 0.0042 1.04 (1.01–1.08) 0.008
 IELSG-score 153 0.74 (0.48–1.16) 0.20
Overall survival
 Female 153 1.12 (0.71–1.76) 0.64
 Age (increase; unit = 10 years) 153 1.36 (1.02–1.82) 0.036 1.32 (0.97–1.77) 0.069
 WHO/ECOG > 1 153 1.29 (0.77–2.16) 0.32
 Multiple lesions 138 1.01 (0.62–1.63) 0.97
 Deep structures involved 153 1.25 (0.79–1.99) 0.34
 Elevated CSF total protein 93 0.64 (0.33–1.26) 0.20
 LDH > ULN 153 1.15 (0.71–1.88) 0.57
 Rituximab 153 0.86 (0.55–1.35) 0.51
 MMSE decrease unit = 1 point) 153 1.06 (1.02–1.10) 0.001 1.06 (1.02–1.10) 0.002
 IELSG-score 153 0.66 (0.40–1.10) 0.11
Fig. 1  a Progression free survival and b overall survival for those with an MMSE-score of < 27 and ≥ 27 at baseline
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the only independent prognostic factor for both PFS and 
OS (Table 1).
Discussion
In this large, prospectively examined study-population of 
PCNSL patients, we found that the MMSE-score at baseline, 
both as a continuous variable and as a categorical variable 
(< 27), is an independent prognostic factor for both PFS and 
OS. MMSE was not evaluated in either of the two most-used 
prognostic scores in PCNSL but our data suggest this factor 
is the most valuable for predicting outcome [2, 3].
Our results are consistent with a previously published 
analysis performed in elderly PCNSL patients: those with 
an MMSE-score ≤ 24 had a worse OS than those with a 
score > 24 [8]. Moreover, in a recent RCT among patients 
up to 60 years the Mattis Dementia Rating Scale, another 
screening tool for neurocognitive impairment, was signifi-
cantly associated with OS, though in univariable analysis 
only. In multivariable analysis, only WHO/ECOG PS was 
associated with both PFS and OS [12]. In this study we 
chose a score of 27 as cut-off of to distinguish patients with 
normal and impaired cognition. This cut-off was based on 
population-based norms [13], and is supported by the find-
ing that the median MMSE score in our population also was 
27. Moreover, in low-grade glioma an MMSE score of 29 
has been found to be predictive for survival [14], compared 
to a score of 27 in our population. This difference is likely 
explained by the more diffuse nature of PCNSL, like Alz-
heimer’s disease, in which a cut-off score of 27 was found 
to be more sensitive to detect cognitive dysfunction [15].
Age and PS are common prognostic factors in oncol-
ogy patients. In our study, both factors were not indepen-
dently prognostic for survival in multivariable analysis, 
although age showed a trend towards significance both for 
PFS (p = 0.061) and OS (p = 0.069). For age, this might be 
explained by the small number of patients ≤ 50 years-old and 
the exclusion of patients > 70-years-old in this study. Some 
other studies also did not find a prognostic effect of age, even 
as categorical variable, although these studies included only 
younger or only elderly patients [8, 12, 16]. Categorizing 
age has been very useful for stratifying patients in clinical 
trials, but ageing is a continuous process. So, from a biologi-
cal perspective, it is more logical to include age as a con-
tinuous variable. Similarly, in contrast to most other stud-
ies [2, 3, 12] we did not find an effect of the WHO/ECOG 
PS on survival. A relatively low power of the test might 
explain this finding. In our study population, only 25% had 
an ECOG > 1, which was the cut-off for the ECOG/ WHO 
performance score that was used in the IELSG-model. This 
small proportion of patients with an ECOG > 1 (patients 
with a WHO/ECOG PS of 4 were ineligible for the HOVON 
105/ALLG NHL 24 study) may have influenced the power 
of the analysis. Although some other studies [8, 16] also 
did not identify a prognostic effect of performance status, it 
remains unexpected.
Besides age, none of the other factors, including the 
IELSG-score showed any relation with survival in our popu-
lation. However, if we compare the MMSE score in the three 
IELSG categories we see a clear difference. This suggests 
that a higher IELSG score at baseline is associated with a 
lower MMSE-score. But, after including all factors in one 
prognostic model, only MMSE remains as prognostic factor.
The MMSE was originally developed as a screening tool 
for cognitive impairment in dementia, and lacks sensitiv-
ity in detecting neurocognitive disturbances, particularly in 
changes over time [17]. A comprehensive neurocognitive 
assessment with standardized tests is more predictive of sur-
vival than brief screening tools [18]. However, the strength 
of the MMSE is that is available in many languages, the 
time to completion is limited, and it can be performed by 
any healthcare worker without extensive training. Therefore, 
the use of the MMSE may be valuable in clinical practice. In 
line with the previously mentioned population-based norm 
(< 27), we would advocate to use the categorized variable 
in prognostic assessment, because of the clinical relevance 
and ease of interpretation.
The major strength of our study is the prospective data 
collection within a large clinical trial resulting in MMSE-
scores for the majority of patients and a uniform treat-
ment and evaluation protocol. A limitation is the rela-
tively small number of patients for prognostication; our 
sample size is smaller than that in the MSKCC (n = 238) 
and IELSG models (n = 378). A down-side of all studies 
based on trial patients is that findings may not be gener-
alizable to the whole PCNSL population. Given the rela-
tively low percentage of patients with ECOG > 1 in this 
substudy and the suggestion of longer survival—though 
Table 2  Multivariate Cox regression analysis for univariately signifi-
cant risk factors with MMSE as a categorical variable for the progres-
sion-free survival and overall survival
Hazard ratio’s (HR) and 95% confidence intervals (CI) are shown 
with their p-value. MMSE mini-mental state examination
Multivariate
HR (95% CI) p
Progression-free survival
 Age (increase; unit = 10 years) 1.24 (0.95–1.60) 0.109
 Rituximab 0.70 (0.47–1.05) 0.087
 MMSE < 27 1.55 (1.02–2.35) 0.040
Overall survival
 Age (increase; unit = 10 years) 1.26 (0.94–1.71) 0.127
 MMSE < 27 1.68 (1.05–2.70) 0.031
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not significant—compared with patients not included (see 
supplemental data), inadvertent bias in the selection of 
patients cannot be excluded. This may be the result of 
more patients in a poor performance status being unable 
or unwilling to undergo the MMSE. However, the magni-
tude of the effect is more likely to be underestimated than 
overestimated with this population of relatively good per-
formance patients. Lastly, we could only include a limited 
number of potential prognostic factors in our analysis for 
statistical reasons. The final choice was based on known 
and/or previously reported relevant factors, and the availa-
bility of factors (e.g. specific information on comorbidities 
was not available). As a result, not all potentially relevant 
factors were included in the analyses and this may have 
overestimated the association between the MMSE score 
and survival. Additionally, WBRT was not included as a 
factor in the multivariable analyses, although a benefit on 
PFS has been described [19]. Because WBRT was only 
part of the treatment in patients under the age of 60, these 
factors were highly correlated. Since we were limited in 
the number of factors that could be included in the multi-
variable models due to limited statistical power, only age 
was included. As a result of this confounding, the effect 
of age may be overestimated.
To conclude, the MMSE is an easily assessable and rel-
evant clinical factor which has not been included in prior 
prognostic studies in patients with PCNSL. In this dataset 
the MMSE-score at baseline is an independent clinical 
prognostic factor in adult PCNSL patients up to 70-years-
old. If validated in another large population, patients 
should be counseled with this effect in mind, and other 
prognostic scores should be re-evaluated.
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